ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

Five-year results of the randomized phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with CML, as compared to imatinib.

An increased rate of adverse effects is seen in patients with differentiated thyroid cancer who are being treated with the tyrosine kinase inhibitor sorafenib.

Adjuvant high-dose interferon alfa-2b did not improve survival in melanoma patients with single tumor–positive lymph nodes found with sentinel lymph node biopsy.

ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.

Treatment with the BCR-ABL tyrosine kinase inhibitors dasatinib, nilotinib, and ponatinib was associated with increased risk for vascular occlusive events in patients with CML compared with imatinib.

This slide show includes highlights from the 2016 ASCO Gastrointestinal Cancers Symposium, including studies on pancreatic cancer patients treated at a high-volume center, Lutathera in patients with midgut neuroendocrine tumors, and more.

Despite clinical trial evidence and recommendations that certain older breast cancer patients can forego radiation therapy after lumpectomy, most older patients continue to receive radiation therapy, according to a new study.

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.

A 48-year-old man presents with pain in the left leg, and a biopsy is performed. What is your diagnosis?

A 59-year-old woman presents with a purplish lesion on her left buttock, and a biopsy is performed. What is your diagnosis?

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.